The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

junotherapeutics.com

Founded Year

2013

Stage

Acq - P2P | Acquired

Total Raised

$310M

Valuation

$0000 

Revenue

$0000 

About Juno Therapeutics

Juno Therapeutics is a clinical-stage company that brings together three cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children's Research Institute – in a partnership to advance a broad pipeline of immunotherapies. Juno will build on the foundation of immunotherapies to develop two distinct and complementary platforms – CARs and TCRs. The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. The company's goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

Juno Therapeutics Headquarters Location

400 Dexter Avenue North Suite 1200

Seattle, Washington, 98109,

United States

206-582-1600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Juno Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Juno Therapeutics in 1 CB Insights research brief, most recently on Jun 2, 2022.

Expert Collections containing Juno Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Juno Therapeutics is included in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

620 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Juno Therapeutics Patents

Juno Therapeutics has filed 107 patents.

The 3 most popular patent topics include:

  • Immunology
  • Immune system
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/23/2015

8/2/2022

Clusters of differentiation, Immunology, Transcription factors, Immune system, Biotechnology

Grant

Application Date

4/23/2015

Grant Date

8/2/2022

Title

Related Topics

Clusters of differentiation, Immunology, Transcription factors, Immune system, Biotechnology

Status

Grant

Latest Juno Therapeutics News

Oxford Biomedica : expands Agreement with Juno Therapeutics, a Bristol Myers Squibb company; adding two new viral vector programmes for Bristol Myers Squibb CAR-T therapies

Jul 21, 2022

07/21/2022 | 04:54am EDT Message : *Required fields The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford, UK - 21 July 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that it has amended and expanded the License and Clinical Supply Agreement ("LSA") with Juno Therapeutics, Inc. ("Juno"), a wholly owned subsidiary of Bristol Myers Squibb Company. The amendment relates to the initiation of two new viral vector programmes for Bristol Myers Squibb CAR-T therapies. The LSA, announced in March 2020 , granted Juno a non-exclusive license to Oxford Biomedica's LentiVector® platform to be used for the manufacture of viral vectors for CAR-T and TCR-T programs in oncology and other indications. Under the terms of the amendment, Oxford Biomedica will receive an undisclosed target nomination fee, as well as potential payments upon the achievement of certain milestones. Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica commented: "Bristol Myers Squibb is a strategically important partner to Oxford Biomedica and we are pleased to announce this expansion of our License & Clinical Supply Agreement. BMS is a proven commercial and clinical leader in the CAR-T field and we are pleased to announce the initiation of the two new programmes, taking the number of programmes we are working on with BMS to six. We look forward to announcing further updates on this important partnership in due course." Enquiries: Stuart Paynter, Chief Financial Officer Sophia Bolhassan, Head of Investor Relations Consilium Strategic Communications: Mary-Jane Elliott / Matthew Neal / Matthew Cole About Oxford Biomedica Oxford Biomedica (LSE:OXB) is aninnovative leading viral vector specialist focused ondelivering life changing therapies to patients. Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials. Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US. Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com . Attachments

  • When was Juno Therapeutics founded?

    Juno Therapeutics was founded in 2013.

  • Where is Juno Therapeutics's headquarters?

    Juno Therapeutics's headquarters is located at 400 Dexter Avenue North, Seattle.

  • What is Juno Therapeutics's latest funding round?

    Juno Therapeutics's latest funding round is Acq - P2P.

  • How much did Juno Therapeutics raise?

    Juno Therapeutics raised a total of $310M.

  • Who are the investors of Juno Therapeutics?

    Investors of Juno Therapeutics include Celgene, Knight Global, Bezos Expeditions, ARCH Venture Partners, Alaska Permanent Fund and 5 more.

  • Who are Juno Therapeutics's competitors?

    Competitors of Juno Therapeutics include Tizona Therapeutics and 3 more.

You May Also Like

Tizona Therapeutics Logo
Tizona Therapeutics

Tizona Therapeutics is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system's function. In cancer, tumor cells evade recognition by controlling cells that suppress the proper function of the immune system. In autoimmune disease, the immune system attacks "self" tissues in the body due to insufficient regulation. Tizona's therapies are designed to regulate these suppressive cells, thereby either activating the body's ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases.

B
BioViva USA

BioViva USA builds gene therapies that work at the cellular level to alleviate those diseases caused by cellular degeneration and genetic disorders. BioViva works to advance research and therapeutics throughout the world to accomplish cures for disease models, improve resilience to cellular defects, as well as to achieve physical improvements in the human body. It was founded in 2015 and is based in Bainbridge Island, Washington.

T
Theracell Advanced Biotechnology

Theracell Advanced Biotechnology provides personalized and precision medicine, enabling individualized treatment with improved outcome. It offers advanced therapy medicinal products (ATMP), which are comprised of gene therapy, somatic cell therapy, and tissue engineered products. Based on viable cells or tissues, their pharmacological, immunologic or metabolic action should be considered as the principal mode of action. The company's therapeutic portfolio spans the areas of orthopedics, dermatology, nephrology, immuno-oncology, and tissue repair and regeneration. Through strategic partnerships Theracell Advanced Biotechnology participates in the global vision of the realization of personalized medicine tailored to individual patient needs.

L
Luminary Therapeutics

Luminary Therapeutics is a biotechnology company based in Minneapolis, Minnesota.

ImCheck Therapeutics Logo
ImCheck Therapeutics

ImCheck Therapeutics designs and develops immunotherapy antibodies positioned at the crossroads of two high-potential immunological fields: g9d2 T cells and a novel super-family of immunomodulators, butyrophilins. Due to their mechanism of action, and notably their ability to simultaneously modulate innate and adaptive immunity, ImCheck's activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and when used in combination to overcome the resistance to this group of agents. In addition, preclinical experiments with ImCheck’s antagonist antibodies have demonstrated potential as treatments for a wide range of autoimmune diseases. ImCheck Therapeutics was founded in 2015 and is based in Marseille, France.

Kite Pharma Logo
Kite Pharma

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing immunotherapies and other oncology treatments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.